Travere Therapeutics (TVTX) Net Cash Flow Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.40% |
| Dec 31, 2025 | 31.31% |
| Sep 30, 2025 | 24.30% |
| Jun 30, 2025 | -41.85% |
| Mar 31, 2025 | -9.45% |
| Dec 31, 2024 | 66.62% |
| Sep 30, 2024 | 18.66% |
| Jun 30, 2024 | -31.21% |
| Mar 31, 2024 | 15.14% |
| Dec 31, 2023 | -40.97% |
| Sep 30, 2023 | -20.16% |
| Jun 30, 2023 | -35.44% |
| Mar 31, 2023 | 32.76% |
| Dec 31, 2022 | -208.59% |
| Sep 30, 2022 | -58.17% |
| Jun 30, 2022 | -29.10% |
| Mar 31, 2022 | 154.23% |
| Dec 31, 2021 | -34.85% |
| Sep 30, 2021 | 91.30% |
| Jun 30, 2021 | -96.50% |
| Mar 31, 2021 | 45.23% |
| Dec 31, 2020 | -2.15% |
| Sep 30, 2020 | -37.21% |
| Jun 30, 2020 | 86.35% |
| Mar 31, 2020 | -46.14% |
| Dec 31, 2019 | 18.13% |
| Sep 30, 2019 | 5.81% |
| Jun 30, 2019 | -30.67% |
| Mar 31, 2019 | -70.34% |
| Dec 31, 2018 | -47.55% |
| Mar 31, 2018 | -76.98% |